Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression

{"Current":[0],"immunotherapies":[1,202],"often":[2],"fail":[3],"in":[4,22,75,138,162],"immunologically":[5],"\\"cold\\",":[6],"macrophage-rich":[7],"tumor":[8,56,60,141],"microenvironments":[9],"(TMEs).":[10],"Multi-targeting":[11],"approaches":[12],"that":[13,186],"modulate":[14],"innate-adaptive":[15],"immune":[16,36,191,212],"activation":[17],"represent":[18],"a":[19,32,39,45,107,139,170,197,205,208],"promising":[20],"frontier":[21],"cancer":[23,145],"immunotherapy.":[24],"Here,":[25],"we":[26],"developed":[27],"phagocytic":[28],"synapse":[29],"enhancers":[30],"(PSEs),":[31],"class":[33],"of":[34,86,143,150,172,211],"modular":[35],"engagers":[37,213],"comprising":[38],"high-affinity":[40],"PD-L1":[41,61],"binder":[42],"coupled":[43],"to":[44,62,123],"macrophage-stimulating":[46],"peptide,":[47],"tuftsin.":[48],"PSEs":[49,72,101,182],"strengthened":[50],"effector-target":[51],"cell":[52],"interactions":[53],"and":[54,83,105,111,118,146,165,175,189,203],"enhanced":[55],"phagocytosis":[57],"by":[58,158],"bridging":[59],"macrophage":[63,103,135],"neuropilin-1":[64],"(NRP1),":[65],"bypassing":[66],"the":[67,81,91,95,124,134,156,163],"classical":[68],"FcγR-dependent":[69],"pathways.":[70,217],"The":[71,114,193],"also":[73],"acted":[74],"cis":[76],"on":[77],"PD-L1+":[78],"macrophages,":[79],"accelerating":[80],"endocytosis":[82],"lysosomal":[84],"compartmentalization":[85],"surface":[87],"PD-L1,":[88],"therefore":[89],"stripping":[90],"immunosuppressive":[92],"checkpoint":[93],"from":[94],"local":[96],"microenvironment.":[97],"Beyond":[98],"physical":[99],"clearance,":[100],"reprogrammed":[102],"phenotype":[104],"triggered":[106],"robust":[108],"pro-inflammatory":[109],"cytokine":[110],"chemokine":[112],"response.":[113],"lead":[115],"molecule,":[116],"longPSE,":[117,129],"its":[119],"half-life-extended":[120],"variant":[121],"fused":[122],"albumin":[125],"binding":[126],"domain,":[127],"ABD-":[128],"showcased":[130],"superior":[131],"efficacy":[132],"than":[133],"enhancer":[136],"magrolimab":[137],"syngeneic":[140],"model":[142,149],"colorectal":[144],"an":[147],"orthotopic":[148],"pancreatic":[151],"cancer.":[152],"PSE":[153],"treatment":[154],"remodeled":[155],"TME":[157],"inducing":[159],"phenotypic":[160],"changes":[161],"lymphoid":[164],"myeloid":[166],"compartments,":[167],"together":[168],"with":[169],"reduction":[171],"tumor-associated":[173],"macrophages":[174],"regulatory":[176],"T":[177],"cells.":[178],"These":[179],"findings":[180],"establish":[181],"as":[183],"bifunctional":[184,194],"molecules":[185],"complement":[187],"innate":[188],"adaptive":[190],"modulation.":[192],"design":[195],"offers":[196],"versatile":[198],"approach":[199],"for":[200,207],"next-generation":[201],"provides":[204],"blueprint":[206],"plug-and-play":[209],"platform":[210],"targeting":[214],"diverse":[215],"cancer-associated":[216]}